Vor Biopharma Inc. (VOR)
VOR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | VOR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001817229 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $79.0M cash; operating cash flow -$29.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 61,434,344 (2026-10-26); 10,410,630 a year earlier; 67,805,687 three years earlier. 3y figure adjusted for split (1-for-20 overall). | Cover page 2026-10-26 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2025-09-19 | Source 2025-09-19 |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-10-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $98.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$86.7M | -$32.7M | $79.0M | No debt tags | Needs four quarters | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | Not filed | -$62.8M | -$25.4M | $107.9M | No debt tags | Needs four quarters | 10-Q 2026-10-30 |
| Q1 2026 2026-03-31 | Not filed | -$219.6M | -$38.2M | $169.9M | No debt tags | Needs four quarters | 10-Q 2026-10-30 |
| Q4 2025 2025-12-31 | Not filed | $1.7B | -$22.8M | $396.5M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$812.7M | -$53.7M | $160.5M | No debt tags | Needs four quarters | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | Not filed | -$1.6B | -$35.2M | $190.6M | No debt tags | Needs four quarters | 10-Q 2026-10-30 |
| Q1 2025 2025-03-31 | Not filed | -$32.5M | -$31.1M | $50.0M | No debt tags | Needs four quarters | 10-Q 2026-10-30 |
| Q4 2024 2024-12-31 | Not filed | -$30.7M | -$24.1M | $81.9M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-30 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 466 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.3% |
| 1 month | +1.9% |
| 3 months | -16.6% |
| Year to date | +48.5% |
| 1 year | +99.2% |
| From 52-week high | -22.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INBX | Inhibrx Biosciences Inc. | $77.66 | -6.77% | $1.1B |
| TSHA | Taysha Gene Therapies Inc. | $4.06 | -0.98% | $1.3B |
| NVAX | Novavax Inc. | $8.06 | -5.45% | $1.3B |
| ODTX | Odyssey Therapeutics Inc. | $19.36 | +1.15% | $930.6M |
| IMTX | Immatics N.V. | $6.17 | -3.44% | $923.2M |
| LYCA | Lycia Therapeutics Inc. | $28.61 | -8.30% | $1.5B |
| IMCR | Immunocore Holdings plc | $28.88 | -3.54% | $1.5B |
| MGTX | MeiraGTx Holdings plc | $8.74 | -4.79% | $854.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier